Released Mar 28, 2024, after the close
10-K filed Mar 28, 2024, 88 days after period end · 0000950170-24-038057
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.16M$7.16M derivedno prior Q4 2022 on fileno prior Q3 2023 on file
Net Income-$10.96M-$10.96M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$12,551,000N/M
Operating Cash Flowderived$73,647,000N/M
Free Cash Flowderived$73,576,000N/M
Margins · derived
Operating margin-175.2%
Net margin-153.0%
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $7.16M | — | — | $1.04M |
| Net Income | -$10.96M | -$22.40M | -$60.26M | -$39.42M |
| EPS Diluted | — | — | — | -$1.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR